Cdk 4/6 inhibitors for adjuvant therapy in early breast cancer—do we have a clear winner?

HIGHLIGHTS

• who: Amol Akhade and colleagues from the BYL Nair Hospital and TN Medical College, Mumbai, Maharashtra, India Departments of and Public Health Sciences, University, Kingston K L , Canada have published the paper: CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?, in the Journal: (JOURNAL)
• what: The authors explore several reasons for this discrepancy in the results of CDK4/6 inhibitors in the adjuvant setting.

SUMMARY

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy (ET) have become the mainstay . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.